Trade Supernus Pharmaceuticals Inc - SUPN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024151% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001929% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 36.05 |
| Open | 35.98 |
| 1-Year Change | 28.18% |
| Day's Range | 35.2 - 35.98 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | 35.52 | -0.23 | -0.64% | 35.75 | 36.00 | 35.15 |
| Nov 14, 2024 | 36.05 | -0.93 | -2.51% | 36.98 | 37.79 | 35.76 |
| Nov 13, 2024 | 37.72 | -0.01 | -0.03% | 37.73 | 38.18 | 36.95 |
| Nov 12, 2024 | 37.79 | 1.23 | 3.36% | 36.56 | 37.90 | 36.51 |
| Nov 11, 2024 | 36.56 | -0.02 | -0.05% | 36.58 | 37.13 | 35.95 |
| Nov 8, 2024 | 36.53 | 0.18 | 0.50% | 36.35 | 36.56 | 35.82 |
| Nov 7, 2024 | 36.32 | -0.92 | -2.47% | 37.24 | 37.31 | 36.16 |
| Nov 6, 2024 | 37.69 | 1.97 | 5.52% | 35.72 | 38.12 | 34.32 |
| Nov 5, 2024 | 34.66 | -3.27 | -8.62% | 37.93 | 38.42 | 33.25 |
| Nov 4, 2024 | 34.66 | 1.24 | 3.71% | 33.42 | 34.89 | 33.42 |
| Nov 1, 2024 | 33.92 | 0.55 | 1.65% | 33.37 | 34.45 | 33.36 |
| Oct 31, 2024 | 34.01 | 0.04 | 0.12% | 33.97 | 34.94 | 33.63 |
| Oct 30, 2024 | 34.83 | 0.81 | 2.38% | 34.02 | 35.44 | 33.68 |
| Oct 29, 2024 | 34.32 | 0.44 | 1.30% | 33.88 | 34.32 | 33.45 |
| Oct 28, 2024 | 34.09 | 0.12 | 0.35% | 33.97 | 34.56 | 33.97 |
| Oct 25, 2024 | 33.88 | 0.21 | 0.62% | 33.67 | 34.47 | 33.08 |
| Oct 24, 2024 | 33.72 | 0.28 | 0.84% | 33.44 | 34.20 | 33.44 |
| Oct 23, 2024 | 33.82 | 0.69 | 2.08% | 33.13 | 33.83 | 33.12 |
| Oct 22, 2024 | 33.67 | 0.72 | 2.19% | 32.95 | 33.96 | 32.93 |
| Oct 21, 2024 | 33.62 | -0.56 | -1.64% | 34.18 | 34.41 | 33.59 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Supernus Company profile
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Supernus Pharmaceuticals Inc revenues increased 12% to $420.7M. Net income decreased 47% to $51M. Revenues reflect Net product sales- Trokendi XR segment increase of 34% to $231.5M, Net product sales-APOKYN segment increase of 70% to $73.3M. Net income was offset by Selling/General/Admin. Expense increase of 47% to $131.4M (expense), Advertising Expense increase of 58% to $59.7M (expense).
Equity composition
Common Stock $0.001 Par, 5/12, 62M auth., 23,912,319 issd. Insiders own approx. 6.73%. IPO:TBA
| Industry: | Proprietary & Advanced Pharmaceuticals |
9715 Key West Avenue
ROCKVILLE
MARYLAND 20850
US
News
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024
US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com